Abstract
In many Western countries, endometrial carcinoma is now considered to be the most common gynecological malignancy, but mortality from this disease is less than that for ovarian malignancies. Nearly 20% of patients with endometrial carcinoma get second primaries, mostly in the breast and colon, indicating common denominators for many of these tumors. Certain factors predispose to this cancer. Many patients are obese, nulliparous, and have a history of irregular menses suggesting a basic abnormality in the hypothalamic-pituitary-ovarian hormonal axis. Long periods of unopposed estrogen stimulation of the endometrium may be a factor in carcinogenesis, since the endometrium is a highly sensitive end-organ to estrogens, regardless of whether they are of gonodal origin or exogenously administered. When the estrogen-induced growth is unopposed by progesterone (due to a lack of ovulations or for other reasons) the endometrium first shows hyperplasia. If the epithelial activity is excessive, adenomatous hyperplasia with prominent mitoses and changes that are difficult to distinguish from frank adenocarcinoma appear. The risk factors are also shared by these two conditions. Although treatment with progesterones may in some cases reverse an adenomatous hyperplasia so that even a desired pregnancy will be possible, in the somewhat older woman hysterectomy is considered to be the safest approach. In particular, the presence of cytonuclear atypia raises concern for premalignancy and progression to can]cer. It has also been proposed that such lesions should be referred to as endometrial intraepithelial neoplasia (EIN).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Emons G, Kullander S, Pahwa GS (1988) GnRH-binding in human endometrial cancer. Abstracts of the 12th world congress of gynecology and obstetrics, 23-28 October 1988, Rio de Janeiro, Brazil, p 560
Gallagher CJ, Oliver RTD, Hope-Stone HF, Oram D, Fowler C (1990) Proceeding of the 2nd international symposium on GnRH analogues in cancer and human reproduction, November 8-11, 1990, Geneva
Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R, Emons G (1991) Specific low affinity binding sites for gonadotropin releasing hormone in human endometrial carcinomata. Eur J Obstet Gynecol Reprod Biol 41:135–142
Perl V, Serially AV, Comaru-Schally AM, Marquez J, Dabancens A, Navarro C (1987) Use of D-Trp6-LH-RH in endometrial adenocarcinoma. 22nd congreso chileno de obstetricia y ginecologia, 1987, Santiago, vol 2
Srkalovic G, Wittliff JL, Schally AV (1990) Detection and partial characterization of receptors for D-Trp6-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50:1841–1846
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kullander, S. (1992). Treatment of Endometrial Cancer with GnRH Analogs. In: Höffken, K. (eds) Peptides in Oncology I. Recent Results in Cancer Research, vol 124. Springer, Milano. https://doi.org/10.1007/978-88-470-2186-0_7
Download citation
DOI: https://doi.org/10.1007/978-88-470-2186-0_7
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2188-4
Online ISBN: 978-88-470-2186-0
eBook Packages: Springer Book Archive